Understanding what each peptide does, and why they work better together, is essential for evaluating whether this protocol is appropriate
Nonetheless, these symptoms led to discontinuation of treatment in 4-8% of patients enrolled in completed obesity trials for semaglutide (Novo Nordisk), and the dual GLP-1/GIP receptor agonist tirzepatide (Eli Lilly)
Effective November 1, 2023 select peptides will not be availablemake your voice heard to change this FDA mandate that impacts patient care
But I do think there are so many important and well described neuronal populations that have the GLP-1 receptor and which are accessible from the periphery
We dont believe BMI alone should determine access to these medications
In Experiment 2, due to limited sample size, data from both sexes were pooled and analyzed using one-way ANOVAs for cumulative curve and acute administration measures